ORIC — Oric Pharmaceuticals, Inc.
No mentions collected in the last 24 hours.
ORIC — 오늘 왜 언급됐나 (2026-10-27)
- 존슨앤존슨이 ESMO에서 전립선암 치료제의 초기 결과를 발표하며 ORIC 주가가 약 32% 급락했다.
- ORIC은 건강 섹터의 주요 변동주 중 하나로 지목되며 소형주 자금 유출 모니터링에서도 언급되었다.
Why people talked about ORIC
- ORIC shares fell approximately 32% after Johnson & Johnson reported promising early results for a competing prostate cancer drug at ESMO.
- JNJ's drug showed a 75% tumor response rate in heavily pretreated patients, posing a direct competitive threat to ORIC's lead drug.
- ORIC was highlighted as a top mover in the health sector with significant declines amidst small-cap stock monitoring reports.